Alba Therapeutics Corp.
This article was originally published in Start Up
Executive Summary
Alba Therapeutics has identified the pathway and a key protein associated with paracellular permeability, which is impaired in autoimmune diseases. It is testing an antagonist of that protein as a therapy for celiac disease and eventually, type 1 diabetes.
You may also be interested in...
The Double-edged Sword of Diabetes Drug Development
Intense interest in new diabetes drugs gives start-ups many choices for technology development or in-licensing, but recent regulatory caution also increases risk.
Understanding How To Develop BTK Inhibitors In MS Is Evolving
Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.
Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.